Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Next Vial vs OlleveCare

Next Vial
Graded #345

Higher grade

vs+13.099999999999994
OlleveCare
Graded #497

Lower grade

The verdict

Next Vial takes it — 59.3/100 to 46.2/100.

Next Vial grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOlleveCare +5
40
45
Dose & formulationNext Vial +12
52
40
Clinical oversightNext Vial +29
82
53
Labs & monitoringNext Vial +3
52
49
FulfillmentNext Vial +48
86
38
Contract termsEven
55
55
Next Vial · left barOlleveCare · right bar

The numbers

MetricNext VialOlleveCare
WeighScore59.3/10046.2/100
GradeCC
Scorecard rank#345#497
Semaglutide$250/mo (compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
Coverage49 states13 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Next Vial

Graded #345 · C

Strengths

  • LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
  • No membership fees — one all-in price covering consultation, medication, and shipping
  • Compounded semaglutide, tirzepatide, and microdose options available
  • Free rushed shipping; serves 49 states nationwide
  • Board-certified physician oversight with ongoing provider support

Where it loses points

  • Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
  • Compounded medications are not FDA-approved
  • Labs and nutritional coaching not disclosed
  • Microdose pricing not published on product page
  • Alaska not listed among served states
OlleveCare

Graded #497 · C

Strengths

  • 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
  • Both semaglutide and tirzepatide offered — switch molecules without switching platforms
  • Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
  • Cash-pay with a superbill option for out-of-network reimbursement
  • Founder Ahmed Emam is named in the footer

Where it loses points

  • Legal entity name not disclosed anywhere — can't be verified in a state registry
  • Pricing not shown before booking — you must enter the intake flow to see the fee
  • Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
  • No medical director or prescribing clinician named — only 'board-certified providers'
  • No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard